Where can I find SZLSF's financial statements?

StageZero Life Sciences Ltd. (SZLSF)'s full income statement, balance sheet, and cash flow statement are on this page in 10-K-style line-item format. Switch between the three statements via the pill toggle above the table.

How much history is available for SZLSF?

StageZero Life Sciences Ltd. (SZLSF) statements are available back to its earliest filed 10-K — typically 10+ years of annual data and 40 quarters of quarterly data. Free-tier users see 5 years and 8 quarters; full history unlocks with a Pro account.

How often does SZLSF update its statements?

StageZero Life Sciences Ltd. files a 10-K annually (full audited year-end statements) and 10-Q reports quarterly (unaudited interim statements). New filings are typically parsed and reflected on this page within 48 hours of SEC submission.

SZLSF

StageZero Life Sciences Ltd.

OTC·Medical, Diagnostics & Research · Healthcare

$0.00$0.00+0.00%

Market cap$123.53K·Market closed·Aug 25 8:00 PM UTC

USD · values shown as reported

Line item	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
Revenue	$185.87K−54.8%	$138.70K−25.4%	$4.15M+2,893.3%	$5.07M+22.1%	$3.80M−25.1%
Cost of revenue	$1.27M−9.9%	$1.10M−13.1%	$3.46M+214.3%	$3.89M+12.6%	$4.20M+7.9%
Gross profit	−$1.08M−8.7%	−$960.91K+11.0%	$695.56K+172.4%	$1.18M+69.3%	−$403.75K−134.3%
Research & development	—	—	$218.70K	$774.54K+254.2%	$351.99K−54.6%
General & administrative	$3.29M−21.1%	$4.18M+27.1%	$4.02M−3.8%	$6.98M+73.6%	$5.91M−15.4%
Selling & marketing	—	—	$14.42K	$1.24M+8,523.5%	$746.41K−40.0%
SG&A (combined)	$3.29M−21.1%	$4.18M+27.1%	$4.21M+0.8%	$8.22M+95.2%	$6.65M−19.1%
Other operating expenses	$12.33K	—	—	$311.34K	$338.88K+8.8%
Total operating expenses	$3.29M−21.1%	$4.18M+27.1%	$4.43M+6.0%	$9.31M+110.0%	$7.34M−21.1%
Operating income	−$4.36M−11.8%	−$5.11M−17.4%	−$3.74M+26.9%	−$7.96M−113.1%	−$7.75M+2.7%
Interest income	—	—	$35.09K	—	—
Interest expense	$1.13M+164.5%	$803.20K−28.9%	$699.39K−12.9%	$200.31K−71.4%	$284.07K+41.8%
Other income / (expense), net	$662.39K−70.0%	$1.41M+112.4%	−$3.13M−322.3%	$479.23K+115.3%	−$3.67M−865.5%
Income before tax	−$3.94M−33.8%	−$3.48M+11.7%	−$6.86M−97.1%	−$7.48M−9.0%	−$11.42M−52.5%
Income tax expense	$1.14M−32.4%	$830.49K−27.3%	—	—	—
Net income	−$3.94M−33.8%	−$3.48M+11.7%	−$6.86M−97.1%	−$7.48M−9.0%	−$11.42M−52.5%

EPS (basic)	−$0.23+4.2%	−$0.16+30.4%	−$0.15+6.3%	−$0.10+33.3%	−$0.11−10.0%
EPS (diluted)	−$0.23+4.2%	−$0.16+30.4%	−$0.15+6.3%	−$0.10+33.3%	−$0.11−10.0%
Weighted avg shares (basic)	17,108,464	26,498,823	44,820,966	70,715,834	99,426,473
Weighted avg shares (diluted)	17,108,464	26,498,823	44,820,966	70,715,834	99,426,473

Depreciation & amortization	$294.96K−18.0%	$305.02K+3.4%	$268.48K−12.0%	$308.35K+14.8%	$420.11K+36.2%
EBITDA	−$2.66M−18.2%	−$2.44M+8.5%	−$6.26M−156.9%	−$5.69M+9.1%	−$10.27M−80.6%

Frequently Asked Questions About SZLSF

Where can I find SZLSF's financial statements?: StageZero Life Sciences Ltd. (SZLSF)'s full income statement, balance sheet, and cash flow statement are on this page in 10-K-style line-item format. Switch between the three statements via the pill toggle above the table.
How much history is available for SZLSF?: StageZero Life Sciences Ltd. (SZLSF) statements are available back to its earliest filed 10-K — typically 10+ years of annual data and 40 quarters of quarterly data. Free-tier users see 5 years and 8 quarters; full history unlocks with a Pro account.
How often does SZLSF update its statements?: StageZero Life Sciences Ltd. files a 10-K annually (full audited year-end statements) and 10-Q reports quarterly (unaudited interim statements). New filings are typically parsed and reflected on this page within 48 hours of SEC submission.

Line item

FY 2018

FY 2019

FY 2020

FY 2021

FY 2022

Trend

Revenue

$185.87K−54.8%

$138.70K−25.4%

$4.15M+2,893.3%

$5.07M+22.1%

$3.80M−25.1%

Cost of revenue

$1.27M−9.9%

$1.10M−13.1%

$3.46M+214.3%

$3.89M+12.6%

$4.20M+7.9%

Gross profit

−$1.08M−8.7%

−$960.91K+11.0%

$695.56K+172.4%

$1.18M+69.3%

−$403.75K−134.3%

Research & development

—

$218.70K

$774.54K+254.2%

$351.99K−54.6%

General & administrative

$3.29M−21.1%

$4.18M+27.1%

$4.02M−3.8%

$6.98M+73.6%

$5.91M−15.4%

Selling & marketing

—

$14.42K

$1.24M+8,523.5%

$746.41K−40.0%

SG&A (combined)

$3.29M−21.1%

$4.18M+27.1%

$4.21M+0.8%

$8.22M+95.2%

$6.65M−19.1%

Other operating expenses

$12.33K

—

$311.34K

$338.88K+8.8%

Total operating expenses

$3.29M−21.1%

$4.18M+27.1%

$4.43M+6.0%

$9.31M+110.0%

$7.34M−21.1%

Operating income

−$4.36M−11.8%

−$5.11M−17.4%

−$3.74M+26.9%

−$7.96M−113.1%

−$7.75M+2.7%

Interest income

—

$35.09K

—

Interest expense

$1.13M+164.5%

$803.20K−28.9%

$699.39K−12.9%

$200.31K−71.4%

$284.07K+41.8%

Other income / (expense), net

$662.39K−70.0%

$1.41M+112.4%

−$3.13M−322.3%

$479.23K+115.3%

−$3.67M−865.5%

Income before tax

−$3.94M−33.8%

−$3.48M+11.7%

−$6.86M−97.1%

−$7.48M−9.0%

−$11.42M−52.5%

Income tax expense

$1.14M−32.4%

$830.49K−27.3%

—

Net income

−$3.94M−33.8%

−$3.48M+11.7%

−$6.86M−97.1%

−$7.48M−9.0%

−$11.42M−52.5%

EPS (basic)

−$0.23+4.2%

−$0.16+30.4%

−$0.15+6.3%

−$0.10+33.3%

−$0.11−10.0%

EPS (diluted)

−$0.23+4.2%

−$0.16+30.4%

−$0.15+6.3%

−$0.10+33.3%

−$0.11−10.0%

Weighted avg shares (basic)

17,108,464

26,498,823

44,820,966

70,715,834

99,426,473

Weighted avg shares (diluted)

17,108,464

26,498,823

44,820,966

70,715,834

99,426,473

Depreciation & amortization

$294.96K−18.0%

$305.02K+3.4%

$268.48K−12.0%

$308.35K+14.8%

$420.11K+36.2%

EBITDA

−$2.66M−18.2%

−$2.44M+8.5%

−$6.26M−156.9%

−$5.69M+9.1%

−$10.27M−80.6%